UnknownNot Applicable

Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

South Korea29 participantsStarted 2015-09

Plain-language summary

To compare the short-term effect of intravitreal aflibercept injection between two subtypes of polypoidal choroidal vasculopathy

Who can participate

Age range

45 Years – 90 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. symptomatic typical PCV accompanying branch vascular network involving subfoveal area
. signed informed consent; and
. over 6 months follow-up period after enrollment.

Exclusion criteria

. retinal diseases other than PCV
. extrafoveal PCV not involving subfoveal area
. massive subretinal hemorrhage blocking polypoidal lesion on ICGA
. severe media opacity such as senile cataract
. previous history of intravitreal injection
. previous intraocular surgery history except cataract surgery which was done more than 3 months.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Regression Rate of Polyp on Indocyanine Green Angiography

Timeframe: 3 months

Trial details

NCT IDNCT02597855

SponsorYeungnam University College of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-12

Results submitted2016-03-22

View on ClinicalTrials.gov More Polypoidal Choroidal Vasculopathy trials